Pacira BioSciences (PCRX) Form 4 on RSU tax withholding shares reported

Rhea-AI Filing Summary

Pacira BioSciences Chief Medical Officer Jonathan Slonin reported an automatic share withholding related to equity compensation. On January 2, 2026, 381 shares of Pacira common stock were withheld at $24.46 per share to cover tax obligations when a restricted stock unit award vested. After this withholding, Slonin beneficially owned 178,523.175 shares of Pacira common stock, which includes 537.166 shares acquired through the company’s employee stock purchase plan in December 2025. This filing reflects routine tax and ownership reporting rather than an open-market trade.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SLONIN JONATHAN

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		F		381(1)	D	$24.46	178,523.175(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

2. Includes 537.166 shares of common stock acquired under the issuer's employee stock purchase plan in December 2025.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Pacira BioSciences (PCRX) disclose in this Form 4 filing?

The filing shows that Chief Medical Officer Jonathan Slonin had 381 shares of Pacira common stock withheld on January 2, 2026 to cover tax obligations upon the vesting of a restricted stock unit award.

Was this an open-market sale of Pacira (PCRX) shares by Jonathan Slonin?

No. The F transaction code and footnote indicate the 381 shares were withheld by the issuer to satisfy tax withholding requirements when restricted stock units vested, rather than sold in the market.

How many Pacira (PCRX) shares does Jonathan Slonin own after this transaction?

Following the reported tax withholding, Jonathan Slonin beneficially owned 178,523.175 shares of Pacira common stock, held in direct ownership form.

What is the significance of the price shown in the Form 4 for Pacira (PCRX)?

The Form 4 reports a price of $24.46 per share for the 381 withheld shares, which is used to calculate the value of the shares applied toward Slonin’s tax withholding obligation on the vesting restricted stock units.

What does the footnote about the employee stock purchase plan mean for Pacira (PCRX)?

One footnote explains that Slonin’s holdings include 537.166 shares of Pacira common stock acquired under the company’s employee stock purchase plan in December 2025, which are part of his total beneficial ownership.

What is Jonathan Slonin’s role at Pacira BioSciences (PCRX)?

Jonathan Slonin is identified in the filing as an officer of Pacira BioSciences, serving as the company’s Chief Medical Officer.